Insider Transactions in Q1 2021 at Karyopharm Therapeutics Inc. (KPTI)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
4,000
-0.56%
|
$48,000
$12.39 P/Share
|
|
Mar 18
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
4,000
-0.56%
|
$48,000
$12.39 P/Share
|
|
Feb 25
2021
|
Michael Kauffman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
57,200
+5.85%
|
-
|
|
Feb 25
2021
|
Michael Kauffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
57,200
+7.37%
|
-
|
|
Feb 25
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
57,200
+7.37%
|
-
|
|
Feb 25
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
57,200
+5.85%
|
-
|
|
Feb 25
2021
|
John Demaree Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,849
+39.78%
|
-
|
|
Feb 25
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,013
+17.41%
|
-
|
|
Feb 25
2021
|
Tanya Lewis EVP, Chief Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
22,013
+32.65%
|
-
|
|
Feb 25
2021
|
Michael Mason EVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
22,013
+29.84%
|
-
|
|
Feb 25
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,013
+16.97%
|
-
|
|
Feb 18
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
9,495
-1.21%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
9,495
-1.62%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
9,495
-1.62%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,495
-1.21%
|
$132,930
$14.83 P/Share
|
|
Feb 18
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
2,887
-5.89%
|
$40,418
$14.83 P/Share
|
|
Feb 18
2021
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,186
-2.24%
|
$16,604
$14.83 P/Share
|
|
Feb 15
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
21,800
+2.7%
|
-
|
|
Feb 15
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,800
+3.59%
|
-
|
|
Feb 15
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
21,800
+3.59%
|
-
|
|
Feb 15
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,800
+2.7%
|
-
|
|
Feb 15
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,675
+16.49%
|
-
|
|
Feb 15
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,850
+8.39%
|
-
|
|
Feb 11
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
6,642
-0.86%
|
$99,630
$15.52 P/Share
|
|
Feb 11
2021
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
6,601
-1.16%
|
$99,015
$15.52 P/Share
|
|
Feb 11
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,601
-1.16%
|
$99,015
$15.52 P/Share
|
|
Feb 11
2021
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,642
-0.86%
|
$99,630
$15.52 P/Share
|
|
Feb 11
2021
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
2,858
-35.07%
|
$42,870
$15.52 P/Share
|
|
Feb 11
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
2,046
-4.94%
|
$30,690
$15.52 P/Share
|
|
Feb 11
2021
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,748
-3.5%
|
$26,220
$15.52 P/Share
|
|
Feb 11
2021
|
Tanya Lewis EVP, Chief Reg. Affairs |
SELL
Open market or private sale
|
Direct |
2,046
-33.06%
|
$30,690
$15.52 P/Share
|
|
Feb 05
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,300
+1.82%
|
-
|
|
Feb 05
2021
|
Michael Kauffman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,300
+2.45%
|
-
|
|
Feb 05
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,300
+2.45%
|
-
|
|
Feb 05
2021
|
Sharon Shacham Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,300
+1.82%
|
-
|
|
Feb 05
2021
|
Michael Mason EVP, CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,150
+50.0%
|
-
|
|
Feb 05
2021
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,650
+12.01%
|
-
|
|
Feb 05
2021
|
Tanya Lewis EVP, Chief Reg. Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
5,650
+47.72%
|
-
|
|
Feb 05
2021
|
Jatin Shah EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,650
+10.18%
|
-
|